



The Swedish Association of Medical Statistics (FMS) and Danish Society for Biopharmaceutical Statistics (DSBS) organize jointly a one-day meeting on the 6th of May 2004 on

Statistical Issues in Drug Development
Key note speaker: Professor Stephen Senn

Program committee: Silvia Garcia Codony , Bernhard Huitfeldt,
Marianne Maehle-Schmidt

Conference language: English

Venue: Restaurang Översten in the center of Malmö,
(<http://www.oversten.se>)

Registration: Register by paying DKK 400 to Nordea, Nærum department, Reg. no. 2266, Account no. : 0062 175 516 and sending an e-mail to Rita Schou at rs@medicon.dk with your name before April 30. Registration fee includes lunch and coffee am and pm.

For more information about the meeting:

Silvia Garcia Codony ; e-mail: sgc@spadillemedimentum.com
Marianne Maehle Schmidt; e-mail: marianne.maehle-schmidt@statisticon.se

See also the website for the respective society:

<http://www.statistikersamfundet.se/fms/>

<http://www.dsbs.dk>

Programme

- **09.15-10.00 Coffee and registration**
Chairperson: Bernhard Huitfeldt, AstraZeneca, Global Clinical Science, Södertälje
- **10.00-10.10 Welcome to the first joint meeting**
Ziad Taib, AstraZeneca R&D Mölndal (FMS President) and Lisbeth Groes, ALK-Abelló (DSBS President)
- **10.10-12.00 Statistical Issues in Drug Development**
Stephen Senn, University of Glasgow
- **12.00-13.00 Lunch**
Chairperson: Silvia Garcia Codony, SpadilleMedimentum, Fredensborg
- **13.00-13.30 Examples of multivariate relative dose-potency estimation**
Anders Källén, AstraZeneca R&D Lund
- **13.30-14.00 Quantifying the predictability of insulin action profiles**
Birgitte Biilman Rönn & Lars Endahl, Novo Nordisk A/S
- **14.00-14.30 A comparison of multiplicity-adjustment methods in a dose finding study with binary endpoint**
Nedjad Losic, SpadilleMedimentum A/S
- **14.30-15.00 Coffee break**
Chairperson: Marianne Maehle-Schmidt, Statisticon, Uppsala
- **15.00-15.30 Interim analyses and other early looks of trial data: contribution or curse?**
Kim Mark Knudsen, Genmab A/S & Kristian Windfeld, Ferring Pharmaceuticals A/S
- **15.30-16.00 Statistical significance and clinical relevance**
Olivier Guilbaud, AstraZeneca R&D Södertälje
- **16.00-16.30 Non-inferiority testing in clinical trials: Some statistical perspectives**
Lars Frison, AstraZeneca R&D, Mölndal

- **16.30-17.00 Round-up discussion**